English
|
Spanish
Login
Register
The content on this site is intended for healthcare professionals only
For the latest
e
cancer COVID-19 resources, click on this link
Home
News
Journal
Video
e
learning
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
e
cancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.
Please login or register. Then you can use this button to confirm you are part of this project.
Register for free
Already have an account?
Login
Videos
[516]
News
[1121]
Articles
[168]
Editorials
[8]
Conferences
[53]
e
learning
[8]
The age of genomic profiling
Prof Cengiz Yakicier - Acıbadem University, Istanbul, Turkey
27 Jan 2020
Identifying BRCA mutations for breast and ovarian cancer
Prof Alena Savanevich - Grodno State Medical University, Grodno, Belarus
27 Jan 2020
Laser therapy for vulvo-vaginal atrophy / genito-urinary syndrome of menopause i...
Prof Deborah Fenlon - Swansea University, Swansea, UK
12 Dec 2019
What should be the HPV vaccine strategy for India?
Dr Rengaswamy Sankaranarayanan - WHO-IARC, Lyon, France
7 Nov 2019
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer
Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain
7 Oct 2019
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma
Dr Jonathan Ledermann - University College Hospital, London, UK
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
4 Oct 2019
Ovarian highlights from ESMO 2019
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
28 Sep 2019
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fall...
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
28 Sep 2019
PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer ...
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
28 Sep 2019
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
28 Sep 2019
More ovarian cancer patients benefit from maintenance combined targeted therapy
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
28 Sep 2019
<
1
...
5
6
7
8
9
...
43
>
More from
e
cancer